Delivery of chemo-sensitizing siRNAs to HER2(+)-breast cancer cells using RNA aptamers

Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers....

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Thiel, Kristina W., Hernandez, Luiza I., Dassie, Justin P., Thiel, William H., Liu, Xiuying, Stockdale, Katie R., Rothman, Alissa M., Hernandez, Frank J., McNamara, James O., Giangrande, Paloma H.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2012
Sujets:
RNA
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3401474/
https://ncbi.nlm.nih.gov/pubmed/22467215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gks294
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires